Erythropoietin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy

Helen Bramlett, W. Dalton Dietrich, C. Edward Dixon, Deborah A. Shear, Kara E. Schmid, Stefania Mondello, Kevin K W Wang, Ronald L. Hayes, John T. Povlishock, Frank C. Tortella, Patrick M. Kochanek

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Experimental studies targeting traumatic brain injury (TBI) have reported that erythropoietin (EPO) is an endogenous neuroprotectant in multiple models. In addition to its neuroprotective effects, it has also been shown to enhance reparative processes including angiogenesis and neurogenesis. Based on compelling pre-clinical data, EPO was tested by the Operation Brain Trauma Therapy (OBTT) consortium to evaluate therapeutic potential in multiple TBI models along with biomarker assessments. Based on the pre-clinical TBI literature, two doses of EPO (5000 and 10,000 IU/kg) were tested given at 15 min after moderate fluid percussion brain injury (FPI), controlled cortical impact (CCI), or penetrating ballistic-like brain injury (PBBI) with subsequent behavioral, histopathological, and biomarker outcome assessments. There was a significant benefit on beam walk with the 5000 IU dose in CCI, but no benefit on any other motor task across models in OBTT. Also, no benefit of EPO treatment across the three TBI models was noted using the Morris water maze to assess cognitive deficits. Lesion volume analysis showed no treatment effects after either FPI or CCI; however, with the 5000 IU/kg dose of EPO, a paradoxical increase in lesion volume and percent hemispheric tissue loss was seen after PBBI. Biomarker assessments included measurements of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) in blood at 4 or 24 h after injury. No treatment effects were seen on biomarker levels after FPI, whereas treatment at either dose exacerbated the increase in GFAP at 24 h in PBBI but attenuated 24-4 h delta UCH-L1 levels at high dose in CCI. Our data indicate a surprising lack of efficacy of EPO across three established TBI models in terms of behavioral, histopathological, and biomarker assessments. Although we cannot rule out the possibility that other doses or more prolonged treatment could show different effects, the lack of efficacy of EPO reduced enthusiasm for its further investigation in OBTT.

Original languageEnglish (US)
Pages (from-to)538-552
Number of pages15
JournalJournal of Neurotrauma
Volume33
Issue number6
DOIs
StatePublished - Mar 15 2016

Fingerprint

Erythropoietin
Brain Injuries
Percussion
Biomarkers
Ubiquitin Thiolesterase
Glial Fibrillary Acidic Protein
Neuroprotective Agents
Therapeutics
Traumatic Brain Injury
Neurogenesis
Protein C
Outcome Assessment (Health Care)
Water
Wounds and Injuries

Keywords

  • biomarker
  • controlled cortical impact
  • fluid percussion
  • neuroprotection
  • penetrating ballistic-like brain injury
  • rat
  • therapy

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Erythropoietin Treatment in Traumatic Brain Injury : Operation Brain Trauma Therapy. / Bramlett, Helen; Dalton Dietrich, W.; Dixon, C. Edward; Shear, Deborah A.; Schmid, Kara E.; Mondello, Stefania; Wang, Kevin K W; Hayes, Ronald L.; Povlishock, John T.; Tortella, Frank C.; Kochanek, Patrick M.

In: Journal of Neurotrauma, Vol. 33, No. 6, 15.03.2016, p. 538-552.

Research output: Contribution to journalArticle

Bramlett, H, Dalton Dietrich, W, Dixon, CE, Shear, DA, Schmid, KE, Mondello, S, Wang, KKW, Hayes, RL, Povlishock, JT, Tortella, FC & Kochanek, PM 2016, 'Erythropoietin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy', Journal of Neurotrauma, vol. 33, no. 6, pp. 538-552. https://doi.org/10.1089/neu.2015.4116
Bramlett, Helen ; Dalton Dietrich, W. ; Dixon, C. Edward ; Shear, Deborah A. ; Schmid, Kara E. ; Mondello, Stefania ; Wang, Kevin K W ; Hayes, Ronald L. ; Povlishock, John T. ; Tortella, Frank C. ; Kochanek, Patrick M. / Erythropoietin Treatment in Traumatic Brain Injury : Operation Brain Trauma Therapy. In: Journal of Neurotrauma. 2016 ; Vol. 33, No. 6. pp. 538-552.
@article{8b8438c8703543f486d7437e3e4bff34,
title = "Erythropoietin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy",
abstract = "Experimental studies targeting traumatic brain injury (TBI) have reported that erythropoietin (EPO) is an endogenous neuroprotectant in multiple models. In addition to its neuroprotective effects, it has also been shown to enhance reparative processes including angiogenesis and neurogenesis. Based on compelling pre-clinical data, EPO was tested by the Operation Brain Trauma Therapy (OBTT) consortium to evaluate therapeutic potential in multiple TBI models along with biomarker assessments. Based on the pre-clinical TBI literature, two doses of EPO (5000 and 10,000 IU/kg) were tested given at 15 min after moderate fluid percussion brain injury (FPI), controlled cortical impact (CCI), or penetrating ballistic-like brain injury (PBBI) with subsequent behavioral, histopathological, and biomarker outcome assessments. There was a significant benefit on beam walk with the 5000 IU dose in CCI, but no benefit on any other motor task across models in OBTT. Also, no benefit of EPO treatment across the three TBI models was noted using the Morris water maze to assess cognitive deficits. Lesion volume analysis showed no treatment effects after either FPI or CCI; however, with the 5000 IU/kg dose of EPO, a paradoxical increase in lesion volume and percent hemispheric tissue loss was seen after PBBI. Biomarker assessments included measurements of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) in blood at 4 or 24 h after injury. No treatment effects were seen on biomarker levels after FPI, whereas treatment at either dose exacerbated the increase in GFAP at 24 h in PBBI but attenuated 24-4 h delta UCH-L1 levels at high dose in CCI. Our data indicate a surprising lack of efficacy of EPO across three established TBI models in terms of behavioral, histopathological, and biomarker assessments. Although we cannot rule out the possibility that other doses or more prolonged treatment could show different effects, the lack of efficacy of EPO reduced enthusiasm for its further investigation in OBTT.",
keywords = "biomarker, controlled cortical impact, fluid percussion, neuroprotection, penetrating ballistic-like brain injury, rat, therapy",
author = "Helen Bramlett and {Dalton Dietrich}, W. and Dixon, {C. Edward} and Shear, {Deborah A.} and Schmid, {Kara E.} and Stefania Mondello and Wang, {Kevin K W} and Hayes, {Ronald L.} and Povlishock, {John T.} and Tortella, {Frank C.} and Kochanek, {Patrick M.}",
year = "2016",
month = "3",
day = "15",
doi = "10.1089/neu.2015.4116",
language = "English (US)",
volume = "33",
pages = "538--552",
journal = "Journal of Neurotrauma",
issn = "0897-7151",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Erythropoietin Treatment in Traumatic Brain Injury

T2 - Operation Brain Trauma Therapy

AU - Bramlett, Helen

AU - Dalton Dietrich, W.

AU - Dixon, C. Edward

AU - Shear, Deborah A.

AU - Schmid, Kara E.

AU - Mondello, Stefania

AU - Wang, Kevin K W

AU - Hayes, Ronald L.

AU - Povlishock, John T.

AU - Tortella, Frank C.

AU - Kochanek, Patrick M.

PY - 2016/3/15

Y1 - 2016/3/15

N2 - Experimental studies targeting traumatic brain injury (TBI) have reported that erythropoietin (EPO) is an endogenous neuroprotectant in multiple models. In addition to its neuroprotective effects, it has also been shown to enhance reparative processes including angiogenesis and neurogenesis. Based on compelling pre-clinical data, EPO was tested by the Operation Brain Trauma Therapy (OBTT) consortium to evaluate therapeutic potential in multiple TBI models along with biomarker assessments. Based on the pre-clinical TBI literature, two doses of EPO (5000 and 10,000 IU/kg) were tested given at 15 min after moderate fluid percussion brain injury (FPI), controlled cortical impact (CCI), or penetrating ballistic-like brain injury (PBBI) with subsequent behavioral, histopathological, and biomarker outcome assessments. There was a significant benefit on beam walk with the 5000 IU dose in CCI, but no benefit on any other motor task across models in OBTT. Also, no benefit of EPO treatment across the three TBI models was noted using the Morris water maze to assess cognitive deficits. Lesion volume analysis showed no treatment effects after either FPI or CCI; however, with the 5000 IU/kg dose of EPO, a paradoxical increase in lesion volume and percent hemispheric tissue loss was seen after PBBI. Biomarker assessments included measurements of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) in blood at 4 or 24 h after injury. No treatment effects were seen on biomarker levels after FPI, whereas treatment at either dose exacerbated the increase in GFAP at 24 h in PBBI but attenuated 24-4 h delta UCH-L1 levels at high dose in CCI. Our data indicate a surprising lack of efficacy of EPO across three established TBI models in terms of behavioral, histopathological, and biomarker assessments. Although we cannot rule out the possibility that other doses or more prolonged treatment could show different effects, the lack of efficacy of EPO reduced enthusiasm for its further investigation in OBTT.

AB - Experimental studies targeting traumatic brain injury (TBI) have reported that erythropoietin (EPO) is an endogenous neuroprotectant in multiple models. In addition to its neuroprotective effects, it has also been shown to enhance reparative processes including angiogenesis and neurogenesis. Based on compelling pre-clinical data, EPO was tested by the Operation Brain Trauma Therapy (OBTT) consortium to evaluate therapeutic potential in multiple TBI models along with biomarker assessments. Based on the pre-clinical TBI literature, two doses of EPO (5000 and 10,000 IU/kg) were tested given at 15 min after moderate fluid percussion brain injury (FPI), controlled cortical impact (CCI), or penetrating ballistic-like brain injury (PBBI) with subsequent behavioral, histopathological, and biomarker outcome assessments. There was a significant benefit on beam walk with the 5000 IU dose in CCI, but no benefit on any other motor task across models in OBTT. Also, no benefit of EPO treatment across the three TBI models was noted using the Morris water maze to assess cognitive deficits. Lesion volume analysis showed no treatment effects after either FPI or CCI; however, with the 5000 IU/kg dose of EPO, a paradoxical increase in lesion volume and percent hemispheric tissue loss was seen after PBBI. Biomarker assessments included measurements of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) in blood at 4 or 24 h after injury. No treatment effects were seen on biomarker levels after FPI, whereas treatment at either dose exacerbated the increase in GFAP at 24 h in PBBI but attenuated 24-4 h delta UCH-L1 levels at high dose in CCI. Our data indicate a surprising lack of efficacy of EPO across three established TBI models in terms of behavioral, histopathological, and biomarker assessments. Although we cannot rule out the possibility that other doses or more prolonged treatment could show different effects, the lack of efficacy of EPO reduced enthusiasm for its further investigation in OBTT.

KW - biomarker

KW - controlled cortical impact

KW - fluid percussion

KW - neuroprotection

KW - penetrating ballistic-like brain injury

KW - rat

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=84962245540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962245540&partnerID=8YFLogxK

U2 - 10.1089/neu.2015.4116

DO - 10.1089/neu.2015.4116

M3 - Article

C2 - 26670694

AN - SCOPUS:84962245540

VL - 33

SP - 538

EP - 552

JO - Journal of Neurotrauma

JF - Journal of Neurotrauma

SN - 0897-7151

IS - 6

ER -